Literature DB >> 29378174

Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans.

Shanshan Zhang1, Jingxiao Wang2, Haichuan Wang3, Lingling Fan4, Biao Fan5, Billy Zeng6, Junyan Tao4, Xiaolei Li4, Li Che4, Antonio Cigliano7, Silvia Ribback8, Frank Dombrowski8, Bin Chen6, Wenming Cong9, Lixin Wei10, Diego F Calvisi11, Xin Chen12.   

Abstract

Primary liver cancer consists mainly of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). A subset of human HCCs expresses a ICC-like gene signature and is classified as ICC-like HCC. The Hippo pathway is a critical regulator of normal and malignant liver development. However, the precise function(s) of the Hippo cascade along liver carcinogenesis remain to be fully delineated. The role of the Hippo pathway in a murine mixed HCC/ICC model induced by activated forms of AKT and Ras oncogenes (AKT/Ras) was investigated. The authors demonstrated the inactivation of Hippo in AKT/Ras liver tumors leading to nuclear localization of Yap and TAZ. Coexpression of AKT/Ras with Lats2, which activates Hippo, or the dominant negative form of TEAD2 (dnTEAD2), which blocks Yap/TAZ activity, resulted in delayed hepatocarcinogenesis and elimination of ICC-like lesions in the liver. Mechanistically, Notch2 expression was found to be down-regulated by the Hippo pathway in liver tumors. Overexpression of Lats2 or dnTEAD2 in human HCC cell lines inhibited their growth and led to the decreased expression of ICC-like markers, as well as Notch2 expression. Altogether, this study supports the key role of the Hippo cascade in regulating the differentiation status of liver tumors.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29378174      PMCID: PMC5866106          DOI: 10.1016/j.ajpath.2017.12.017

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  68 in total

1.  Canonical notch signaling functions as a commitment switch in the epidermal lineage.

Authors:  Cédric Blanpain; William E Lowry; H Amalia Pasolli; Elaine Fuchs
Journal:  Genes Dev       Date:  2006-11-01       Impact factor: 11.361

2.  Hippo pathway activity influences liver cell fate.

Authors:  Dean Yimlamai; Constantina Christodoulou; Giorgio G Galli; Kilangsungla Yanger; Brian Pepe-Mooney; Basanta Gurung; Kriti Shrestha; Patrick Cahan; Ben Z Stanger; Fernando D Camargo
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

3.  Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis.

Authors:  Stefano Piccolo; Michelangelo Cordenonsi; Sirio Dupont
Journal:  Clin Cancer Res       Date:  2013-06-24       Impact factor: 12.531

4.  Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.

Authors:  Agrin Moeini; Daniela Sia; Zhongyang Zhang; Genis Camprecios; Ashley Stueck; Hui Dong; Robert Montal; Laura Torrens; Iris Martinez-Quetglas; M Isabel Fiel; Ke Hao; Augusto Villanueva; Swan N Thung; Myron E Schwartz; Josep M Llovet
Journal:  J Hepatol       Date:  2017-01-23       Impact factor: 25.083

Review 5.  The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.

Authors:  Noa Furth; Yael Aylon
Journal:  Cell Death Differ       Date:  2017-06-23       Impact factor: 15.828

6.  Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway.

Authors:  Donghwa Kim; Shaokun Shu; Marc D Coppola; Satoshi Kaneko; Zeng-Qiang Yuan; Jin Q Cheng
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

7.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

8.  miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells.

Authors:  T Higashi; H Hayashi; T Ishimoto; H Takeyama; T Kaida; K Arima; K Taki; K Sakamoto; H Kuroki; H Okabe; H Nitta; D Hashimoto; A Chikamoto; T Beppu; H Baba
Journal:  Br J Cancer       Date:  2015-06-30       Impact factor: 7.640

9.  Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.

Authors:  Junjie Hu; Li Che; Lei Li; Maria G Pilo; Antonio Cigliano; Silvia Ribback; Xiaolei Li; Gavinella Latte; Marta Mela; Matthias Evert; Frank Dombrowski; Guohua Zheng; Xin Chen; Diego F Calvisi
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

10.  Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans.

Authors:  L Che; B Fan; M G Pilo; Z Xu; Y Liu; A Cigliano; A Cossu; G Palmieri; R M Pascale; A Porcu; G Vidili; M Serra; F Dombrowski; S Ribback; D F Calvisi; X Chen
Journal:  Oncogenesis       Date:  2016-12-05       Impact factor: 7.485

View more
  9 in total

Review 1.  Role of YAP1 Signaling in Biliary Development, Repair, and Disease.

Authors:  Laura Molina; Kari Nejak-Bowen; Satdarshan P Monga
Journal:  Semin Liver Dis       Date:  2022-01-24       Impact factor: 6.512

2.  NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma.

Authors:  Shikai Hu; Laura Molina; Junyan Tao; Silvia Liu; Mohammed Hassan; Sucha Singh; Minakshi Poddar; Aaron Bell; Daniela Sia; Michael Oertel; Reben Raeman; Kari Nejak-Bowen; Aatur Singhi; Jianhua Luo; Satdarshan P Monga; Sungjin Ko
Journal:  Gastroenterology       Date:  2022-05-10       Impact factor: 33.883

3.  The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans.

Authors:  Shu Zhang; Jie Zhang; Katja Evert; Xiaolei Li; Pin Liu; Andras Kiss; Zsuzsa Schaff; Cindy Ament; Yi Zhang; Monica Serra; Matthias Evert; Nianyong Chen; Feng Xu; Xin Chen; Junyan Tao; Diego F Calvisi; Antonio Cigliano
Journal:  Am J Pathol       Date:  2020-04-10       Impact factor: 4.307

4.  SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model.

Authors:  Meng Xu; Jingxiao Wang; Zhong Xu; Rong Li; Pan Wang; Runze Shang; Antonio Cigliano; Silvia Ribback; Antonio Solinas; Giovanni Mario Pes; Katja Evert; Haichuan Wang; Xinhua Song; Shu Zhang; Li Che; Rosa Maria Pascale; Diego Francesco Calvisi; Qingguang Liu; Xin Chen
Journal:  Cancer Res       Date:  2019-08-05       Impact factor: 12.701

5.  TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.

Authors:  Binyong Liang; Yi Zhou; Manning Qian; Meng Xu; Jingxiao Wang; Yi Zhang; Xinhua Song; Haichuan Wang; Shumei Lin; Chuanli Ren; Satdarshan P Monga; Bruce Wang; Matthias Evert; Yifa Chen; Xiaoping Chen; Zhiyong Huang; Diego F Calvisi; Xin Chen
Journal:  J Hepatol       Date:  2021-02-10       Impact factor: 30.083

6.  The Human Novel Gene LNC-HC Inhibits Hepatocellular Carcinoma Cell Proliferation by Sequestering hsa-miR-183-5p.

Authors:  Xi Lan; Nan Wu; Litao Wu; Kai Qu; Ezra Kombo Osoro; Dongxian Guan; Xiaojuan Du; Bo Wang; Sifan Chen; Ji Miao; Juan Ren; Li Liu; Haiyun Li; Qilan Ning; Dongmin Li; Shemin Lu
Journal:  Mol Ther Nucleic Acids       Date:  2020-03-20       Impact factor: 8.886

Review 7.  Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research.

Authors:  Oihane Erice; Adrian Vallejo; Mariano Ponz-Sarvise; Michael Saborowski; Arndt Vogel; Diego F Calvisi; Anna Saborowski; Silvestre Vicent
Journal:  Cancers (Basel)       Date:  2019-11-26       Impact factor: 6.639

Review 8.  Notch signaling in the pathogenesis, progression and identification of potential targets for cholangiocarcinoma (Review).

Authors:  Peeranate Vanaroj; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Mol Clin Oncol       Date:  2022-01-19

9.  Fascin1 empowers YAP mechanotransduction and promotes cholangiocarcinoma development.

Authors:  Arianna Pocaterra; Gloria Scattolin; Patrizia Romani; Cindy Ament; Silvia Ribback; Xin Chen; Matthias Evert; Diego F Calvisi; Sirio Dupont
Journal:  Commun Biol       Date:  2021-06-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.